2007
DOI: 10.2217/17460913.2.5.513
|View full text |Cite
|
Sign up to set email alerts
|

The Expanding Role of Lipid II as a Target for Lantibiotics

Abstract: Lipid II is an essential cell-wall precursor required for the growth and replication of both Gram-positive and Gram-negative bacteria. Compounds that use lipid II to selectively target bacterial cells for destruction represent an important class of antibiotics. Clinically, vancomycin is the most important example of an antibiotic that operates in this manner. Despite being considered the ‘antibiotic drug of last resort’, significant bacterial resistance to vancomycin now manifests itself worldwide. In this pap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
45
0
1

Year Published

2008
2008
2016
2016

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 64 publications
(46 citation statements)
references
References 105 publications
(101 reference statements)
0
45
0
1
Order By: Relevance
“…The mevalonate pathway is required to make undecaprenyl pyrophosphate and lipid II (43). The consequence of this upregulation in the fabT deletion mutant strain might be increased production of lipid II, potentially leading to (i) in- creased resistance to cationic antimicrobial peptides (CAMPs) and lantibiotics that target lipid II (44)(45)(46) and (ii) higher levels of peptidoglycan (PG) and other envelope components that also are targets for CAMPs (47,48). The gene Spy_0124 (sloR), encoding a regulator involved in metal homeostasis, was also significantly upregulated by 10.3-fold in the fabT deletion mutant during mid-exponential phase at 35°C.…”
Section: Identification Of Acquired Polymorphisms In Serotype M1 Stramentioning
confidence: 99%
“…The mevalonate pathway is required to make undecaprenyl pyrophosphate and lipid II (43). The consequence of this upregulation in the fabT deletion mutant strain might be increased production of lipid II, potentially leading to (i) in- creased resistance to cationic antimicrobial peptides (CAMPs) and lantibiotics that target lipid II (44)(45)(46) and (ii) higher levels of peptidoglycan (PG) and other envelope components that also are targets for CAMPs (47,48). The gene Spy_0124 (sloR), encoding a regulator involved in metal homeostasis, was also significantly upregulated by 10.3-fold in the fabT deletion mutant during mid-exponential phase at 35°C.…”
Section: Identification Of Acquired Polymorphisms In Serotype M1 Stramentioning
confidence: 99%
“…This system is transcriptionally activated by exposure to alkaline shock, organic solvents, detergents, secretion stress, and notably lipid II cycle inhibitors such as the antibiotics vancomycin and bacitracin, the bacteriocin nisin, and cationic antimicrobial peptides (39,51); hence, its cogname, lipid IIinteracting antibiotics LiaRS. Lipid II contains the complete peptidoglycan (PG) subunit linked to the membrane-embedded lipid carrier C 55 -isoprenyl phosphate (36,60). The molecule "flips" between the cytoplasmic and extracellular faces of the cell membrane in a dynamic process (referred to as the lipid II cycle) essential for translocating PG precursors for cell wall biosynthesis (36,60).…”
mentioning
confidence: 99%
“…Lipid II contains the complete peptidoglycan (PG) subunit linked to the membrane-embedded lipid carrier C 55 -isoprenyl phosphate (36,60). The molecule "flips" between the cytoplasmic and extracellular faces of the cell membrane in a dynamic process (referred to as the lipid II cycle) essential for translocating PG precursors for cell wall biosynthesis (36,60). The Lipid II cycle is considered the rate-limiting step of PG polymer biosynthesis and, consequently, the subject of intense scrutiny in the development of novel inhibitors that target or exploit this process (9).…”
mentioning
confidence: 99%
“…Nisin, obtained by fermentation of Lactobacillus lactis on natural substrates such as milk or dextrose, is widely used as a safe food preservation additive (Cleveland et al 2001), since orally administered nisin is completely degraded by digesting enzymes in the stomach. Nisin binds to the pyrophosphate moiety of lipid II (Scheme 5) forming a phosphate cage that prevents the release of the peptidoglycan subunits and leads to the formation of a pore in the membrane via intermembrane assembly of a nisin-lipid II 8:4-complex (Hsu et al 2004;Bauer and Dicks 2005;Martin and Breukink 2007). …”
Section: Lessons Learned From Druggable Targets In Bacteriamentioning
confidence: 99%